Latest news with #BiotechCompanies
Globe and Mail
21 hours ago
- Business
- Globe and Mail
Chronic Myeloid Leukemia Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies
DelveInsight's, 'Chronic Myeloid Leukaemia Pipeline Insight, 2025' report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Myeloid Leukaemia pipeline landscape. It covers the Chronic Myeloid Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Chronic Myeloid Leukemia Treatment Landscape @ Chronic Myeloid Leukemia Pipeline Outlook Key Takeaways from the Chronic Myeloid Leukemia Pipeline Report On 15 August 2025, M.D. Anderson Cancer Center conducted a phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase. On 13 August 2025, Novartis Pharmaceuticals announced a study is to optimize the treatment of asciminib in patients with chronic myelogenous leukemia in chronic phase (CML-CP) previously treated with 2 or more Tyrosine Kinase Inhibitors (TKIs). DelveInsight's Chronic Myeloid Leukemia pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Myeloid Leukemia treatment. The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others. Promising Chronic Myeloid Leukemia Pipeline Therapies such as Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others. Discover groundbreaking developments in Chronic Myeloid Leukemia Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Chronic Myeloid Leukemia Ongoing Clinical Trials Assessment Chronic Myeloid Leukemia Emerging Drugs Profile Navtemadlin : Kartos Therapeutics Navtemadlin (KRT-232) is a novel, potent, and selective oral MDM2 inhibitor. Currently, the drug is undergoing an Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML). Ropeginterferon alfa 2b : AOP Orphan Pharmaceuticals Ropeginterferon alfa-2b was discovered by PharmaEssentia Corp. based in Taiwan. BESREMi (Ropeginterferon alfa-2b) is a novel, long-acting, mono-pegylated proline interferon .Its pharmacokinetic properties offer a new level of tolerability. The Chronic Myeloid Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Myeloid Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Myeloid Leukemia Treatment. Chronic Myeloid Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Myeloid Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Myeloid Leukemia market Stay informed about the Chronic Myeloid Leukemia pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Chronic Myeloid Leukemia Unmet Needs Chronic Myeloid Leukemia Companies Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others. Chronic Myeloid Leukaemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Molecule Type Chronic Myeloid Leukemia Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Product Type Transform your understanding of the Chronic Myeloid Leukemia Pipeline! See the latest progress in drug development and clinical research @ Chronic Myeloid Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Myeloid Leukemia Pipeline Report Coverage- Global Chronic Myeloid Leukemia Companies- Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, Incyte Corporation, Sana Biotechnology, Novartis, Nerviano Medical Sciences, Sun Pharma Advanced Research Company and others. Chronic Myeloid Leukemia Pipeline Therapies- Imatinib mesyl, Dasatinib, Nilotinib, decitabine (5-aza-2'deoxycytidine), Asciminib, Bosutinib, Peginterferon alfa-2a, and others. Chronic Myeloid Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Myeloid Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Oncology Research–Access the Full Chronic Myeloid Leukemia Pipeline Analysis Today! @ Chronic Myeloid Leukemia Drugs and Companies Table of Contents Introduction Executive Summary Chronic Myeloid Leukaemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic Myeloid Leukaemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name : Company Name Mid Stage Products (Phase I/ II) Navtemadlin: Kartos Therapeutics Early Stage Products (Phase I) Drug Name: Company Name Preclinical and Discovery Stage Products Drug Name: Company Name Inactive Products Chronic Myeloid Leukaemia Key Companies Chronic Myeloid Leukaemia Key Products Chronic Myeloid Leukaemia- Unmet Needs Chronic Myeloid Leukaemia- Market Drivers and Barriers Chronic Myeloid Leukaemia- Future Perspectives and Conclusion Chronic Myeloid Leukaemia Analyst Views Chronic Myeloid Leukaemia Key Companies About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
30-06-2025
- Business
- Yahoo
Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6% from 2025, Says Meticulous Research®
Market Growth Driven by Rising Biopharmaceutical Demand, Recombinant Protein Development, and Government Life Science Research Funding REDDING, Calif., June 30, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Protein Expression Market by System (Mammalian [CHO, HEK 293], Non-mammalian [Bacterial, Insect, Yeast]), Offering (Kits & Reagents, Vectors, Competent Cells, Services), Application (Industrial, Therapeutic, Research), and End User—Global Forecast to 2032", the Protein Expression market is projected to reach $5.0 billion by 2032, growing at a robust CAGR of 7.6% during the forecast period from 2025. The significant growth of the protein expression market is driven by the rapidly expanding biopharmaceutical sector, increasing demand for recombinant proteins across therapeutic and research applications, and substantial government initiatives supporting life science research and development. The market's expansion is fueled by the growing adoption of biosimilars in oncology and autoimmune diseases, emerging opportunities in underpenetrated economies, and the critical need for advanced protein synthesis technologies across pharmaceutical research, biotechnology development, and industrial applications. The industry is experiencing transformational growth through advanced mammalian cell expression systems, innovative recombinant protein technologies, and specialized solutions for therapeutic protein production. Leading companies are investing heavily in contract research organization partnerships while expanding manufacturing capabilities to meet the surging demand for biopharmaceuticals and developing customized protein expression platforms for diverse research and industrial applications. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Advanced Protein Synthesis Technologies The protein expression market represents a critical evolution in biopharmaceutical development and biotechnology research. As the healthcare industry faces increasing demand for personalized medicine and novel therapeutic proteins, protein expression systems offer comprehensive platforms that address the growing complexity of recombinant protein production, biosimilar development, and advanced research applications across therapeutic and industrial sectors. Market leaders are investing substantially in mammalian cell expression technologies, advanced recombinant DNA systems, and sustainable protein production methods, establishing manufacturing capabilities that can deliver high-yield, high-quality protein synthesis solutions for pharmaceutical companies, biotechnology firms, and academic research institutions. This technological advancement is making sophisticated protein expression systems increasingly accessible to emerging biopharmaceutical companies while delivering enterprise-grade performance and comprehensive regulatory compliance capabilities. Dynamic Growth Across Key Market Segments Based on system type, the Mammalian Cell Expression System segment dominates the market in 2025, capturing the largest share due to their low risk of cross-contamination, elimination of post-translational modification requirements, and wider acceptance for therapeutic applications. Mammalian systems, particularly CHO (Chinese Hamster Ovary) and HEK 293 (Human Embryonic Kidney) cells, provide superior protein folding capabilities and native glycosylation patterns essential for therapeutic protein production, making them indispensable for biopharmaceutical manufacturing and clinical research applications. Based on products and services, the Reagents segment is expected to dominate the market in 2025, reflecting their frequent utilization across research, therapeutic development, and industrial protein production processes. The widespread adoption of specialized reagents for protein expression, purification, and analysis drives consistent demand across all end-user segments. Based on application, the Research segment is projected to register the highest CAGR during the forecast period, driven by expanding R&D expenditure, emergence of new disease targets, and increasing focus on pharma-academic collaborations for advanced protein research and drug discovery initiatives. Based on end-user, the Contract Research Organizations (CROs) segment is expected to exhibit the highest CAGR, reflecting the growing trend of pharmaceutical and biotechnology companies outsourcing protein expression services to specialized providers, supported by government initiatives expanding research activities and cost-optimization strategies in drug development. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents exceptional growth opportunities through biosimilar development expansion, emerging economy penetration, and advancement of specialized expression systems for complex therapeutic proteins. Companies are discovering new revenue streams through contract manufacturing services, customized expression platforms, and comprehensive protein production ecosystems while establishing advanced capabilities for large-scale biopharmaceutical manufacturing. Key market drivers include: Expanding Biopharmaceutical Market: Rapid growth in biologics development, biosimilar production, and personalized medicine creating unprecedented demand for scalable, high-quality protein expression systems across therapeutic applications Rising Recombinant Protein Demand: Increasing adoption of recombinant proteins in therapeutics, vaccines, and industrial applications due to advantages including reduced immune reaction risk, elimination of protein contaminants, and shorter production lead times Government Research Funding: Substantial public and private investment in life science research, biotechnology development, and healthcare innovation driving demand for advanced protein expression technologies in academic and research institutions Biosimilar Market Growth: Significant expansion of biosimilar therapeutics in oncology, autoimmune diseases, and rare conditions, supported by favorable regulatory frameworks and cost advantages compared to originator biologics Emerging Economy Opportunities: Rapid biopharmaceutical industry development in China, India, and other emerging markets creating substantial demand for protein expression systems and contract research services Contract Research Expansion: Growing trend of pharmaceutical companies outsourcing protein expression services to specialized CROs for cost optimization, risk mitigation, and access to advanced technologies Regional Market Leadership and Emerging Growth Asia-Pacific emerges as the fastest-growing region during the forecast period, driven by substantial investments in life science research across China and India, growing preference for recombinant technology advantages, and expanding biopharmaceutical manufacturing capabilities. The region benefits from increasing government initiatives supporting biosimilar development, rising pharmaceutical R&D expenditure, and growing demand for biologics across diverse therapeutic areas. Asia-Pacific's rapid growth is further propelled by the development of multinational clinical centers, accelerated approval processes for specialty medicines, and introduction of Marketing Authorization Holder (MAH) frameworks enabling efficient biosimilar commercialization. The region's emerging economies offer significant advantages including infrastructure development investments, competitive labor costs, improving adherence to global manufacturing standards, and increasing regulatory oversight supporting international market access. North America represents a substantial established market supported by mature biopharmaceutical industries, comprehensive regulatory frameworks, and concentration of leading pharmaceutical and biotechnology companies requiring advanced protein expression technologies. The region's robust research infrastructure creates significant opportunities for specialized protein expression solutions and contract research services. Europe maintains strong market presence driven by established biopharmaceutical industries, comprehensive regulatory standards, and emphasis on innovative therapeutic development. The region's diverse biotechnology sectors, including biosimilar development and specialized therapeutics, create substantial demand for advanced protein expression technologies. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global protein expression market features a sophisticated competitive ecosystem comprising established biotechnology leaders, specialized protein expression technology providers, and innovative contract research organizations. This diverse landscape fosters rapid technological advancement and comprehensive solution development across therapeutic, research, and industrial applications. Industry leaders are implementing integrated protein expression platforms that combine advanced mammalian cell systems, specialized reagents, and comprehensive service offerings. Companies are pursuing strategic partnerships with pharmaceutical companies and academic institutions while addressing evolving regulatory requirements across diverse therapeutic applications and international markets. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global protein expression market include Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (U.S.), Takara Holdings Inc. (Japan), GenScript Biotech Corporation (U.S.), Qiagen N.V. (Germany), Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), and BECTON, DICKINSON AND COMPANY (U.S.). Latest Industry Developments Recent market developments reflecting industry innovation include: Biosimilar Manufacturing Expansion: Major biopharmaceutical companies expanding manufacturing facilities to meet growing biosimilar demand, including strategic partnerships such as Biocon Ltd. and Mylan N.V.'s biosimilar business combination creating larger-scale production capabilities Contract Research Organization Growth: Rapid expansion of CRO services in emerging economies, driven by pharmaceutical companies' increasing focus on outsourcing protein expression services for cost optimization and risk mitigation Advanced Expression System Development: Investment in next-generation mammalian cell expression technologies offering enhanced protein yields, improved quality control, and streamlined production processes for complex therapeutic proteins Emerging Market Penetration: Strategic expansion into underpenetrated markets across Asia-Pacific and Latin America, capitalizing on growing biopharmaceutical demand, increasing aging populations, and rising disposable income supporting healthcare access Academia-Pharma Collaboration: Increasing partnerships between pharmaceutical companies and academic research institutions for advanced protein research, drug discovery, and therapeutic development leveraging specialized expression technologies Related Reports: DNA Sequencing Market Forecast: Next-Generation Sequencing Technologies Analysis Through 2032 Protein Assays Market Analysis: Technology Analysis Through 2032 Digital Therapeutics Market: Software-Based Therapeutic Applications Analysis Through 2031 About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- sales@ Our Website: with us on LinkedIn- Source: Logo: View original content: SOURCE Meticulous Market Research Pvt. Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
